autologous cord blood mononuclear cells

also known as ACBMNC

Developed for: bronchopulmonary dysplasia
Investigated by: Guangdong Women and Children Hospital · BoAi Hospital of Zhongshan · Dongguan Women and Children Hospital · Foshan Fuxing Chancheng Central Hospital · Foshan Women's and Children's Hospital · Guangdong Cord Blood Bank
+8 more
· Guangzhou Huadu Women and Children Hospital · Hexian Memorial Affiliated Hospital of Southern Medical University · Heyuan Women and Children Hospital · Huangdu Distric Women and Children Hospital · Huizhou first Women and Children Hospital · Huizhou second Women and Children Hospital · Longgang Distric Women and Children Hospital,Shenzhen · Shunde Women and Children Hospital

202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT05087498	Nov 2021 → Aug 2022	—	Guangdong Women and Children Hospital	Completed	No outcome recorded
Phase 32 trials
Phase 3	NCT05071638	Oct 2021 → Mar 2023	bronchopulmonary dysplasia	Guangdong Women and Children Hospital	Unknown	No outcome recorded
Phase 3	NCT04440670	Jun 2020 → Dec 2023	bronchopulmonary dysplasia	Guangdong Women and Children Hospital	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	autologous cord blood mononuclear cells	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04440670 ↗ 2 NCT05071638 ↗ NCT05087498 ↗
Known as	ACBMNC	“Those assigned to the ACBMNC group will receive intravenous autologous cord blood mononuclear cells infusion within 24 h after process.” NCT05087498 ↗ 1 “autologous cord blood mononuclear cells(ACBMNC) infusion” NCT05071638 ↗
Modality	Cell therapy	“intravenous autologous cord blood mononuclear cells infusion” NCT04440670 ↗
Route	Intravenous	“receive intravenous autologous cord blood mononuclear cells infusion” NCT04440670 ↗